Poor solubility of therapeutic substances imposes an increasing challenge on the pharmaceutical industry. Around 40 % of approved drugs and even more candidates within the pipeline suffer from this pharmakokinetic obstacle . This has shifted the focus of scientists to the development of novel drug delivery systems (DDS) that function as carriers to efficiently transport hydrophobic drugs to their therapeutic target .